Literature DB >> 15146010

Evolution of MRI changes and development of bilateral hippocampal sclerosis during long lasting generalised status epilepticus.

B Pohlmann-Eden1, A Gass, C N A Peters, R Wennberg, I Blumcke, I Bluemcke.   

Abstract

This report describes a previously healthy 28 year old patient with a 5 month period of intractable generalised status epilepticus (SE) of unknown aetiology with fatal outcome. Repeated magnetic resonance imaging (MRI) showed no pre-existing abnormality, but did show progressive cortical and hippocampal atrophy and T2 hyperintensity in both hippocampal formations, suggestive of progressive tissue damage. Post-mortem histopathological analysis revealed substantial neuronal cell loss including CA1 and CA4 sectors of the hippocampus compatible with bilateral hippocampal sclerosis. There was no evidence of systemic complications including arterial hypotension and hypoxia, hypoglycaemia, hyperpyrexia, or other confounding factors to account for these findings. This case provides further evidence of SE induced hippocampal damage in humans.

Entities:  

Mesh:

Year:  2004        PMID: 15146010      PMCID: PMC1739069          DOI: 10.1136/jnnp.2003.015354

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  3 in total

Review 1.  Treatment of Refractory and Super-refractory Status Epilepticus.

Authors:  Samhitha Rai; Frank W Drislane
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

Review 2.  [Management of refractory status epilepticus from a neurologic and neuropediatric perspective].

Authors:  B Pohlmann-Eden; U Stephani; I Krägeloh-Mann; B Schmitt; U Brandl; M Holtkamp
Journal:  Nervenarzt       Date:  2007-08       Impact factor: 1.214

3.  Hippocampal volume loss following childhood convulsive status epilepticus is not limited to prolonged febrile seizures.

Authors:  Michael Yoong; Marina M Martinos; Richard F Chin; Christopher A Clark; Rodney C Scott
Journal:  Epilepsia       Date:  2013-10-28       Impact factor: 5.864

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.